369 related articles for article (PubMed ID: 29861388)
41. Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Maselli D; Atieh J; Clark MM; Eckert D; Taylor A; Carlson P; Burton DD; Busciglio I; Harmsen WS; Vella A; Acosta A; Camilleri M
Obesity (Silver Spring); 2022 Aug; 30(8):1608-1620. PubMed ID: 35894080
[TBL] [Abstract][Full Text] [Related]
42. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
[TBL] [Abstract][Full Text] [Related]
43. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
Patel D; Smith A
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1193-1204. PubMed ID: 34231442
[No Abstract] [Full Text] [Related]
44. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
45. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Christensen RM; Juhl CR; Torekov SS
Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
[TBL] [Abstract][Full Text] [Related]
46. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
[TBL] [Abstract][Full Text] [Related]
47. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
Gill L; Mackey S
J Womens Health (Larchmt); 2021 Jul; 30(7):1016-1027. PubMed ID: 33626287
[TBL] [Abstract][Full Text] [Related]
48. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis.
Hainerová I; Larsen LH; Holst B; Finková M; Hainer V; Lebl J; Hansen T; Pedersen O
J Clin Endocrinol Metab; 2007 Sep; 92(9):3689-96. PubMed ID: 17579204
[TBL] [Abstract][Full Text] [Related]
49. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
50. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Farr OM; Upadhyay J; Rutagengwa C; DiPrisco B; Ranta Z; Adra A; Bapatla N; Douglas VP; Douglas KAA; Nolen-Doerr E; Mathew H; Mantzoros CS
Diabetes Obes Metab; 2019 Nov; 21(11):2459-2464. PubMed ID: 31282006
[TBL] [Abstract][Full Text] [Related]
51. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating.
Lubrano-Berthelier C; Dubern B; Lacorte JM; Picard F; Shapiro A; Zhang S; Bertrais S; Hercberg S; Basdevant A; Clement K; Vaisse C
J Clin Endocrinol Metab; 2006 May; 91(5):1811-8. PubMed ID: 16507637
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.
Ottney A
Am J Health Syst Pharm; 2013 Dec; 70(23):2097-103. PubMed ID: 24249759
[TBL] [Abstract][Full Text] [Related]
53. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
[TBL] [Abstract][Full Text] [Related]
54. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Jensterle M; Salamun V; Kocjan T; Vrtacnik Bokal E; Janez A
J Ovarian Res; 2015 Jun; 8():32. PubMed ID: 26032655
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.
Hall MJ; Adin CA; Borin-Crivellenti S; Rudinsky AJ; Rajala-Schultz P; Lakritz J; Gilor C
Domest Anim Endocrinol; 2015 Apr; 51():114-21. PubMed ID: 25625650
[TBL] [Abstract][Full Text] [Related]
56. Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
Le TDV; Liu D; Besing GK; Raghavan R; Ellis BJ; Ceddia RP; Collins S; Ayala JE
Elife; 2023 Nov; 12():. PubMed ID: 37930356
[TBL] [Abstract][Full Text] [Related]
57. Liraglutide: A New Option for the Treatment of Obesity.
Nuffer WA; Trujillo JM
Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
[TBL] [Abstract][Full Text] [Related]
58. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
Svane MS; Johannesen HH; Hansen AE; Martinussen C; Bojsen-Møller KN; Hansen ML; Deacon CF; Keller SH; Klausen TL; Loft A; Kjaer A; Löfgren J; Madsbad S; Holst JJ; Wewer Albrechtsen NJ
Int J Obes (Lond); 2022 Nov; 46(11):2058-2062. PubMed ID: 35982119
[TBL] [Abstract][Full Text] [Related]
59. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.
Tilinca MC; Tiuca RA; Burlacu A; Varga A
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34209532
[TBL] [Abstract][Full Text] [Related]
60. The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK Biobank population.
Chami N; Preuss M; Walker RW; Moscati A; Loos RJF
PLoS Med; 2020 Jul; 17(7):e1003196. PubMed ID: 32692746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
